AR098868A1 - PHARMACEUTICAL COMPOSITION IN DRY POWDER FOR INHALATION - Google Patents

PHARMACEUTICAL COMPOSITION IN DRY POWDER FOR INHALATION

Info

Publication number
AR098868A1
AR098868A1 ARP140104803A ARP140104803A AR098868A1 AR 098868 A1 AR098868 A1 AR 098868A1 AR P140104803 A ARP140104803 A AR P140104803A AR P140104803 A ARP140104803 A AR P140104803A AR 098868 A1 AR098868 A1 AR 098868A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
salmeterol
dry powder
pharmaceutically acceptable
inhalation
Prior art date
Application number
ARP140104803A
Other languages
Spanish (es)
Inventor
Blandine Ivanoff Nathalie
Vives Blazquez Montserrat
Arlt Matthias
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of AR098868A1 publication Critical patent/AR098868A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica en polvo seco para inhalación, que comprende salmeterol o una sal farmacéuticamente aceptable del mismo y propionato de fluticasona en mezcla con un vehículo en polvo seco farmacéuticamente aceptable, que proporciona una dosis emitida de salmeterol / propionato de fluticasona equivalente a aproximadamente 16 / 280 mgramos o a 16 / 140 mgramos. Reivindicación 4: La composición farmacéutica según las reivindicaciones 1 a 3, en la que la sal farmacéuticamente aceptable de salmeterol es xinafoato de salmeterol. Reivindicación 6: La composición farmacéutica según con la reivindicación 5, en la que la lactosa está en forma de monohidrato de a-lactosa. Reivindicación 10: La composición farmacéutica según cualquiera de las reivindicaciones anteriores, en la que el diámetro medio de las partículas de xinafoato de salmeterol y/o propionato de fluticasona está dentro de 2 - 5 mm. Reivindicación 14: Un método de tratamiento de una enfermedad respiratoria seleccionada de asma y la enfermedad pulmonar obstructiva crónica en un paciente en necesidad de tal tratamiento, que comprende administrar dos veces al día una dosis emitida de una composición farmacéutica en polvo seco como se define en las reivindicaciones precedentes.A dry powder pharmaceutical composition for inhalation, comprising salmeterol or a pharmaceutically acceptable salt thereof and fluticasone propionate in admixture with a pharmaceutically acceptable dry powdered carrier, which provides an emitted dose of fluticasone salmeterol / propionate equivalent to about 16 / 280 mgrams or 16/140 mgrams. Claim 4: The pharmaceutical composition according to claims 1 to 3, wherein the pharmaceutically acceptable salt of salmeterol is salmeterol xinafoate. Claim 6: The pharmaceutical composition according to claim 5, wherein the lactose is in the form of a-lactose monohydrate. Claim 10: The pharmaceutical composition according to any of the preceding claims, wherein the average diameter of the particles of salmeterol xinafoate and / or fluticasone propionate is within 2-5 mm. Claim 14: A method of treating a respiratory disease selected from asthma and chronic obstructive pulmonary disease in a patient in need of such treatment, comprising administering twice a day an emitted dose of a dry powder pharmaceutical composition as defined in the preceding claims.

ARP140104803A 2013-12-19 2014-12-19 PHARMACEUTICAL COMPOSITION IN DRY POWDER FOR INHALATION AR098868A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382533 2013-12-19

Publications (1)

Publication Number Publication Date
AR098868A1 true AR098868A1 (en) 2016-06-22

Family

ID=49886823

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140104803A AR098868A1 (en) 2013-12-19 2014-12-19 PHARMACEUTICAL COMPOSITION IN DRY POWDER FOR INHALATION
ARP140104802A AR098867A1 (en) 2013-12-19 2014-12-19 PHARMACEUTICAL COMPOSITION IN DRY POWDER FOR INHALATION

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP140104802A AR098867A1 (en) 2013-12-19 2014-12-19 PHARMACEUTICAL COMPOSITION IN DRY POWDER FOR INHALATION

Country Status (4)

Country Link
AR (2) AR098868A1 (en)
TW (2) TW201609201A (en)
UY (2) UY35900A (en)
WO (2) WO2015091285A1 (en)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688V0 (en) 1979-02-05 1979-02-05 Chiesi Paolo Parma INHALER FOR PULVERULENT MEDICINAL SUBSTANCES, WITH COMBINED DOSER FUNCTION.
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (en) 1984-10-04 1986-09-12 Orion Yhtymae Oy DOSERINGSANORDNING
DE3927170A1 (en) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg INHALATOR
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IT1237118B (en) 1989-10-27 1993-05-18 Miat Spa MULTI-DOSE INHALER FOR POWDER DRUGS.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (en) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg GAS-FREE INHALATION DEVICE
DE69132850T2 (en) 1990-09-26 2002-05-29 Pharmachemie Bv Cyclone powder inhaler
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (en) 1992-11-24 1994-05-26 Bayer Ag Multiple dosage powder inhaler - has acceleration channel and dwell chamber for uniformly high drug dispersion
CZ287848B6 (en) 1992-12-18 2001-02-14 Schering Corp Inhalator of powder substances
ATE209518T1 (en) 1995-06-21 2001-12-15 Asta Medica Ag MEDICINAL POWDER CARTRIDGE WITH INTEGRATED DOSING DEVICE AND POWDER INHALER
DE10129703A1 (en) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Atomizing system for a powder mixture and method for dry powder inhalers
ITMI20010357U1 (en) 2001-06-28 2002-12-30 Plastiape Spa INHALER DEVICE
EP2319584A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, ciclesonide and tiotropium
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
KR101214823B1 (en) 2004-07-16 2012-12-24 알미랄, 에스.에이. Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
TR201000681A2 (en) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Dry powder formulations inhaled.
US20130064870A1 (en) * 2010-05-20 2013-03-14 Sun Pharma Advanced Research Company Limited Dry powder inhalation composition

Also Published As

Publication number Publication date
UY35901A (en) 2015-07-31
TW201609201A (en) 2016-03-16
UY35900A (en) 2015-07-31
TW201605432A (en) 2016-02-16
WO2015091285A1 (en) 2015-06-25
WO2015091287A1 (en) 2015-06-25
AR098867A1 (en) 2016-06-22

Similar Documents

Publication Publication Date Title
DOP2016000175A (en) (2S) -N - [(1S) -1-CIANO-2-FENILETIL] -1,4-OXAZEPAN-2-CARBOXAMIDS AS INHIBITORS OF DIPEPTIDIL PEPTIDASE 1
MX2016004316A (en) Dry powder inhaler.
CL2009000601A1 (en) Inhalable pharmaceutical composition in dry powder form comprising aclidinium bromide and a carrier, providing a nominal metered dose of aclinium equivalent to approximately 200 ug of aclinium bromide; its use in COPD and asthma; multi-dose dry powder inhaler device.
EA201591729A1 (en) APPLICABLE FOR INHALATION OF ANGLOMERATES OF PARTICLES OF POROUS MEDIA AND THINLY-CUTTED MEDICINE
BR112017004048A2 (en) alginate oligomer inhalable powder formulations
EA201390049A1 (en) DRY POWDER PREPARATION CONTAINING PHOSPHODESTERASE INHIBITOR
CL2013003497A1 (en) Combination pharmaceutical product in the form of dry powder for administration by means of an inhaler comprising a umeclidinium salt of a defined group and 100 mcg / dose of fluticasone furoate, without other additional assets; use for the treatment of inflammatory or respiratory diseases.
CO2017008395A2 (en) Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoate
NI201400139A (en) NEW FORM OF DOSAGE AND FORMULATION OF ABEDITEROL
CL2013002542A1 (en) Use of an inhalable pharmaceutical composition containing glycopyrrolate or a salt thereof for the treatment or prophylaxis of tachycardia in patients with chronic obstructive pulmonary disease, asthma, cystic fibrosis and related airway diseases.
BR112015027017A2 (en) inhalable pharmaceutical compositions and inhaler devices containing the same
AR100368A1 (en) TREATMENT OF RESPIRATORY DISORDERS
BR112015018120A2 (en) multicomponent crystalline particles for inhalation therapy, pharmaceutical composition, dry powder inhaler, pressurized metered dose inhaler, methods of treating a respiratory disease or disorder or a lung disease or disorder in a patient, and of preparing the particles
AR098868A1 (en) PHARMACEUTICAL COMPOSITION IN DRY POWDER FOR INHALATION
EA201591871A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BUDESONIDE AND FORMOTHEROL
TR201712424A2 (en) DRY POWDER INHALATION COMPOSITIONS
CO2017004512A2 (en) Pharmaceutical composition containing budesonide and formoterol
AR094287A1 (en) METHODS AND COMPOSITIONS FOR OXIBUTININE ADMINISTRATION
AR102903A1 (en) DRY POWDER INHALER
TH173838A (en) Dry powder nebulizer
TH1401007107A (en) New form, dosage form and formulation formulation of AB Dieterol

Legal Events

Date Code Title Description
FB Suspension of granting procedure